Potdar Ankit, Chen Ke-Cheng, Kuo Shuenn-Wen, Lin Mong-Wei, Liao Hsien-Chi, Huang Pei-Ming, Lee Yi-Hsuan, Wang Hsiu-Po, Han Ming-Lun, Cheng Chia-Hsien, Hsu Chih-Hung, Huang Ta-Chen, Hsu Feng-Ming, Lu Shao-Lun, Lee Jang-Ming
Department of Gastroenterology, Global Hospital, Mumbai, India.
Division of Thoracic Surgery, Department of Surgery, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.
Front Oncol. 2023 Jul 12;13:1111998. doi: 10.3389/fonc.2023.1111998. eCollection 2023.
Circumferential radial margin (CRM) involvement by tumor after resection for esophageal cancer has been suggested as a significant prognostic factor. However, the prognostic value of CRM involvement after surgery with neoadjuvant concurrent chemoradiotherapy (CCRT) is unclear. This study aimed to evaluate the prognostic value of and survival outcomes in CRM involvement as defined by the Royal College of Pathologists (RCP) and the College of American Pathologists (CAP) for patients with esophageal cancer undergoing neoadjuvant CCRT and esophagectomy.
A total of 299 patients with esophageal cancer who underwent neoadjuvant CCRT followed by esophagectomy between 2006 and 2016 were enrolled in our study. The CRM status of the specimens obtained was determined pathologically according to both the CAP and RCP criteria. Survival analyses were performed and compared according to the two criteria.
Positive CRM was found in 102 (34.1%) and 40 (13.3%) patients according to RCP and CAP criteria, respectively. The overall and progression-free survival rates were significantly lower in the CRM-positive group than in the CRM-negative group according to both the RCP and CAP criteria. However, under multivariate analysis, in addition to pathological T and N staging of the tumor, only CAP-defined CRM positivity was a significant prognostic factor with adjusted hazard ratios of 2.64 (1.56-4.46) and 2.25 (1.34-3.78) for overall and progression-free survival, respectively (P < 0.001).
In patients with esophageal cancer undergoing neoadjuvant CRT followed by esophagectomy, CAP-defined CRM positivity is an independent predictor of survival. Adjuvant therapy should be offered to patients with positive CRM.
食管癌切除术后肿瘤侵犯环周切缘(CRM)被认为是一个重要的预后因素。然而,新辅助同步放化疗(CCRT)后CRM侵犯的预后价值尚不清楚。本研究旨在评估皇家病理学家学院(RCP)和美国病理学家学会(CAP)定义的CRM侵犯对接受新辅助CCRT和食管切除术的食管癌患者的预后价值和生存结果。
本研究纳入了2006年至2016年间共299例行新辅助CCRT后食管切除术的食管癌患者。根据CAP和RCP标准对获取标本的CRM状态进行病理判定。根据这两个标准进行生存分析并比较。
根据RCP和CAP标准,分别有102例(34.1%)和40例(13.3%)患者CRM阳性。根据RCP和CAP标准,CRM阳性组的总生存率和无进展生存率均显著低于CRM阴性组。然而,在多变量分析中,除了肿瘤的病理T和N分期外,只有CAP定义的CRM阳性是一个显著的预后因素,总生存和无进展生存的调整后风险比分别为2.64(1.56 - 4.46)和2.25(1.34 - 3.78)(P < 0.001)。
在接受新辅助CRT后食管切除术的食管癌患者中,CAP定义的CRM阳性是生存的独立预测因素。CRM阳性患者应接受辅助治疗。